This article is more than 5 years old. Information may no longer be current.
VIDEO: Entyvio effective in ‘real-world’ Crohn’s, UC study
PHILADELPHIA — In this exclusive video perspective from the American College of Gastroenterology Annual Scientific Meeting, Andres Yarur, MD, of the Medical College of Wisconsin, discusses the results of the EVOLVE study, which explored the real-world outcomes of patients taking Entyvio for the treatment of Crohn’s disease or ulcerative colitis.
“We know from other studies that [Entyvio; vedolizumab, Takeda] works in both patients with prior exposure to biologics and those that are naive,” Yarur told Healio Gastroenterology and Liver Disease. “It’s important to know the real outcomes of patients in our population that are receiving the drug today and not only receiving the drug specifically for a clinical trial.”
For the trial, researchers enrolled patients from the United States and Canada with either CD or UC who were taking vedolizumab as their first biologic therapy. They explored several outcomes, including persistence of treatment, mucosal healing and response.
“Another important observation is about 20% of patients required dose escalation,” Yarur said. “Almost all of those patients recaptured response after the dose was changed.”
Reference :
Yarur A, et al. PI1356. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 5-10, 2018; Philadelphia.
Disclosure: The study was funded by Takeda.